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ABSTRACT: Gonadotropin withdrawal induces changes in gene
expression in all 3 major cell types of the testis. Knowledge of the
genes affected, in both the presence and absence of additional
progestogen, will give insight into the regulation of human testicular
function and aid development of novel contraceptive methods. We
have undertaken a whole-genome analysis of RNA expression in
testicular biopsies from normal men and after 4 weeks of gonado-
tropin suppression induced by gonadotropin-releasing hormone
antagonist plus testosterone administration sufficient to cause
marked suppression of spermatogenesis. Microarray analysis shows
that interindividual variability is markedly low, and the response to
treatment is focused on a small subset of genes particularly related
to pathways in steroidogenesis and cholesterol biosynthesis or
metabolism, the Leydig cell gene INSL3, and genes involved in early
meiosis or Sertoli–germ cell junctions. These changes in expression
were confirmed by quantitative reverse transcriptase polymerase
chain reaction. No major changes in gene expression were identified
in men additionally treated with a progestogen, although FLJ35767,
an expressed sequence tag that is expressed in the germ cell
compartment, did show a small but significant additional effect of
progestogen. Overall, the results of this investigation disclose a
remarkably stringent regulation of testicular gene expression,
revealing the genes most sensitive to gonadotropin withdrawal,
and might reflect the most labile pathways in the regulation of
testicular function.
Key words: Microarray analysis, steroidogenesis, testicular
function.
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The molecular mechanisms by which the gonadotro-pins luteinizing hormone (LH) and follicle-stimu-
lating hormone (FSH) support the testicular production
of steroids and gametes in humans are poorly under-
stood. However, such knowledge is important for
improved understanding of the regulation of testicular
function and for the development of safe and efficacious
contraceptive methods.
LH receptors are present on Leydig cells, where they
control steroid biosynthesis and thus the production of
testosterone. Testosterone and FSH receptors are found
on Sertoli and peritubular cells, but there are no
receptors for any of these hormones on germ cells
(Themmen and Huhtaniemi, 2000; Collins et al, 2003),
with the exception of mature human sperm, which have
recently been shown to have functional androgen
receptors (Aquila et al, 2007). This indicates that the
effects of these hormones on immature germ cells must
be indirect, in that all are required for quantitatively
normal spermatogenesis (Matsumoto et al, 1983, 1984).
Gonadotropin suppression results in suppression to
azoospermia in most but not all men (Anderson and
Baird, 2002). Suppression can be achieved by the
administration of testosterone alone or with a gonado-
tropin-releasing hormone (GnRH) antagonist, but the
addition of a progestogen increases spermatogenic
suppression and is currently the most promising
approach toward a hormonal male contraceptive (Nie-
schlag et al, 2003). It has been suggested that the degree
of spermatogenic suppression in some progestogen
regimens is greater than can be accounted for by
gonadotropin suppression, which could indicate that
progestogens act directly on the testis (McLachlan et al,
2004). Both nuclear and membrane progesterone
receptors have been found on spermatozoa and on
Sertoli and some Leydig cells in the human testis (Shah
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et al, 2005) and progestogens have direct inhibitory
effects on Leydig cell function in a murine cell line (El-
Hefnawy et al, 2000). We have recently provided direct
evidence for a progestogenic effect on 5a-reductase
expression in the testis (Walton et al, 2006) that might
reduce the amplifying effect of conversion of testoster-
one to dihydrotestosterone and thus contribute to
greater suppression of spermatogenesis.
To identify a more comprehensive picture of the
effects in humans of suppression of gonadotropins by
administration of a GnRH antagonist and of the
addition of progestogen, we performed microarray
analysis of gene expression on testis biopsies and show
that the pharmacological effects are focused on a select
number of pathway-specific genes indicating stringent
regulation of testicular gene expression.
Methods
Study Design, Drug Treatment, and Testis Biopsy
The study protocol has been described in detail previously
(Walton et al, 2006). In brief, 30 men (mean age 38 years)
requesting vasectomy were recruited, and written informed
consent was obtained. The study had ethical approval from the
Lothian Regional Ethics Committee. Pretreatment investiga-
tions demonstrated that all had normal semen analysis and
reproductive hormone concentrations. Subjects were random-
ized by sealed envelopes into 3 groups. Controls received no
drug treatment before testis biopsy. A second group (CT)
received cetrorelix 3 mg SC (Cetrotide, Serono Europe Ltd,
London, United Kingdom) twice each week and testosterone
enanthate 200 mg IM (Cambridge Laboratories, Wallsend,
United Kingdom) repeated after 2 weeks; the third group
(CTD) took the progestogen desogestrel 300 mg orally (Cera-
zette, 4 6 75 mg, Organon NV, Oss, The Netherlands) each
day for the 28-day duration of the treatment period in addition
to the other agents.
One subject withdrew for personal reasons. After 4 weeks of
drug treatment, further blood and semen samples were
analyzed, and testis biopsies were carried out on the remaining
29 men under local anesthetic at the time of vasectomy with a
14-gauge needle (Tru-Cut, Allegiance Healthcare Corporation,
McGraw Park, Illinois). Tissue samples were immediately
frozen and stored at 280uC.
RNA Samples
Total RNA was extracted from testis biopsies as described
(Walton et al, 2006). Quality was confirmed on RNA 6000
Nanochips in the Agilent 2100 Bioanalyzer (both from Agilent
Technologies UK Ltd, West Lothian, United Kingdom).
Only very high quality RNA (RNA integrity number .7.5)
preparations were considered for microarray screening. Five
RNA samples from each of the control, CT, and CTD groups
were used for screening the microarrays, along with the 5
‘‘nonsuppressors’’ from the treatment groups (3 CT, 2 CTD)
who did not show a reduction in sperm concentrations to
below the reference range (Walton et al, 2006).
Microarray Hybridization and Analysis
Affymetrix Human genome U133 plus 2.0 microarrays
(Affymetrix UK Ltd, High Wycombe, United Kingdom)
containing 54 675 probes representing approximately 39 000
genes, were hybridized to 15 mg fragmented biotin-labeled
cRNA prepared from each RNA and spiked with eukaryotic
hybridization control in a volume of 200 mL for 16 hours.
After hybridization, the arrays were washed on the Genechip
Fluidics Station 450 and scanned with the Genechip Scanner
3000 all according to the manufacturer’s protocols (Affymetrix
UK Ltd).
Raw microarray data were processed and analyzed with R
2.1.1 statistical environment (http://www.R-project.org) and
Bioconductor 1.6 microarray libraries (Gentleman et al, 2004).
Numerical quality control steps were applied to each of the 20
samples. Arrays were normalized and converted to probe-level
data with Robust Multi-Array Average (RMA; Irizarry et al,
2003). To reduce statistical multiple testing and algorithmic
problems in downstream analysis, a nonspecific filter to
remove genes expressed at low levels (signal , log2 100) in
all of the samples was applied. This nonspecific filter is set
quite stringently to remove low-signal genes and thus reduce
the number of false positives, given the relatively low sample
size in each group. It reduces the number of genes available for
comparison from about 19 000 that pass the basic Affymetrix
quality criteria (MAS5 Present/Marginal/Absent calls) to 5824
after nonspecific filtering but gives more reliable results.
To identify candidate genes that change in response to the
various treatments, differential expression (by at least 2-fold)
and its statistical significance for each gene was calculated on
the basis of an empirical Bayes test (Smyth, 2004), which is
robust for small sample sizes. Analysis involved 3 different
stages. Stage 1 testing compared gene expression between
controls and each of the treatment groups (control n5 5, CT n
5 7, CTD n 5 7), as well as between the 2 treatment groups.
Stage 2 testing repeated these comparisons with nonsuppressed
patients removed (CT-ns n5 4, CTD-ns n5 5). Stage 3 testing
explicitly compared all nonsuppressed patients (ns n 5 5) to
the ‘‘suppressed’’ patients in each of the 2 treatment groups
(CT-s n 5 4, CTD-s n 5 5). A reduction in the potential
number of false positive results was achieved by correcting the
significance test P values in relation to the number of genes
tested simultaneously (n 5 5824) (Benjamini and Yekutieli,
2005).
Functional characterization of significantly expressed tran-
scripts was performed with the resource tool DAVID from the
National Institute for Allergy and Infectious Diseases
(NIAID) (http://niaid.abcc.ncifcrf.gov/). DAVID examines
the overrepresentation of gene ontology pathways within a
set of transcripts and provides statistical evaluation of the
presence of these transcripts. Statistical significance was based
on P # .05. Analyses were made with the use of the filtered set
of 5824 genes.
Clustering analysis was next performed: By tagging the
statistically significant genes and then isolating genes that
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cluster alongside them, it is possible to identify additional
genes that are potentially coregulated. These can be missed by
statistical group means testing but could be biologically
interesting. This was carried out with the open source Java
application Biolayout Express3D (Goldovsky et al, 2005;
Freeman et al, in press), which is specifically designed for the
construction, visualization, clustering, and analysis of tran-
scription networks generated from microarray datasets. The
networks created by the software consist of nodes (represent-
ing transcripts) that are connected by edges (which represent
similarities in expression profiles across multiple conditions).
The analysis was performed on the entire RMA normalized
data set (54 675 gene probes) from all of the sample arrays (n
5 20). The statistically significant genes in the original
differential expression list were flagged, allowing them to be
identified in the network graphs produced in Biolayout
Express3D. Clustering graphs where then produced with a
Pearson threshold of 0.9 and a Markov Clustering Algorithm
(MCL) inflation of 1.7, and those containing the flagged gene
set were identified. Additional coregulated genes were thus
identified, and the extended probe lists from these clusters were
then analyzed with DAVID pathway analysis software to
identify enrichment of gene ontologies within the lists.
Finally, an additional nonparametric means of verification
of the data was obtained by assessing differential gene
expression of the original data with the independent rank
product method (Breitling et al, 2004). Briefly, this technique
ranks each gene in each of the replicate samples. The product
of these ranks is then calculated. Statistical significance is
assigned by comparing the observed rank product value with
a bootstrapped null distribution of rank product values for
each gene, and the genes are sorted, with the highest ranking
genes being placed at the top of the list.
Real-Time Quantitative Reverse Transcriptase
Polymerase Chain Reaction
First-strand cDNA (+/2 reverse transcriptase), prepared
from all testis biopsy samples as described previously
(Walton et al, 2006), was used to confirm array results by
real-time quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR). This was performed with the Lightcycler
(Roche Diagnostics, East Sussex, United Kingdom). Reverse-
transcribed RNA samples were diluted 1:10 in nuclease-free
water (Promega Ltd, Southampton, United Kingdom). Dilut-
ed first strand cDNA (1 mL) was added to a final volume of
10 mL containing 50 mg/mL BSA and 0.5 mM each of forward
and reverse primer in 16 Platinum SYBR Green qPCR
SuperMix UDG (Invitrogen, Paisley, United Kingdom) in
duplicate. Primers (Table 1) were either previously published
or designed with the use of online Primer3 software. mRNA
concentration was calculated relative to that of the ribosomal
protein RPL32. RPL32 had previously proved to be the most
consistent reference gene for these samples (Walton et al,
2006).
Results of these analyses are presented (x¯ 6 SEM).
Treatment effects on gene expression data were initially
compared by analysis of variance (ANOVA). Significant
treatment group effects suggested by ANOVA were further
investigated by unpaired t tests, with cube root transformation
to normalize the distribution. For all comparisons, P , .05
was considered significant.
Results
Spermatogenic Suppression
Marked and similar suppression of spermatogenesis was
seen in both treated groups, although there was some
interindividual heterogeneity. Median sperm concentra-
tion fell to 0.6 6 106/mL in the CT group and to 2.6 6
106/mL in the CTD group (both P , .01 compared with
pretreatment). However 3 subjects in the CT group and
2 in the CTD group maintained sperm concentrations
within the reference range (.20 6 106/mL) at day 28,
whereas sperm concentrations were less than 5 6 106/
mL in all others. This allowed classification of 14 men as
‘‘suppressors’’ and 5 as nonsuppressors (Walton et al,
2006).
Preliminary Array Analysis
Five high-quality RNA samples were chosen from each
treatment group (control, CT, and CTD) along with
RNA from each of the 5 nonsuppressors for analysis on
Affymetrix microarrays; thus, a total of 20 samples were
analyzed. After data processing and analysis, 1 sample
from the CT group showed a poor RNA digestion plot
and was excluded from further analysis. After data
quality control, normalization, and nonspecific filtering,
5824 probes—10.6% from the total 54 675 probes on the
chip—showed expression of greater than log2(100) for at
least 1 sample.
These 5824 probes (supplementary Table 1) represent
the predominant genes expressed in the adult human
testis. Assignment of gene ontology pathways to each gene
allowed them to be grouped and for biological processes
statistically overrepresented in the testis to be identified
(Table 2). Not surprisingly, these included genes involved
in sexual reproduction, with cell death genes also highly
represented. Other significant processes were growth
regulation, enzyme regulation, cell physiology, and
metabolism.
A striking finding on initial analysis was that
interindividual variability was remarkably low. The
median coefficient of variance within each group was
6.5% for controls, 6.7% for the CT group, and 7.8% for
the CTD group, with 95th percentile CV values of 14%,
12.9%, and 15.2%, respectively. The average correlation
between samples in a group was greater than 0.99 for
control and CT groups and greater than 0.98 for the
CTD group. This level of variation is in marked contrast
to other tissue biopsy types, which show far greater
variability (Whitney et al, 2003; Radich et al, 2004;
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Critchley et al, 2006; P.G., unpublished data) and
supports the biological significance of the array data.
Analysis of the Effect of Gonadotropin Suppression
Expression of very few genes was altered between the
groups, as demonstrated by volcano plots (Figure 1a
and b). Few genes showed significant 2-fold or greater
differences between controls and treatment groups,
although a greater number of genes showed significant
differences less than 2-fold. No significant differences
were identified between CT and CTD treatment groups
at this stage (Figure 1c).
Stage 1 testing identified only 15 genes that showed at
least a 2-fold change in gene expression between
controls and 1 or both of the treatment groups
(Figure 2). Many of these genes are known to be
involved in steroidogenesis and cholesterol metabolism
(CYP17A1, DHCR24, HSD17B6, STAR, CYP11A1,
HMGCS2). One gene, CYP17A1, had already been
shown to be down-regulated in the CT and CTD groups
by qRT-PCR (Walton et al, 2006). However, other
genes in that study showing changes in expression level
in the treatment groups were not highlighted by this
screen because of sensitivity differences between the 2
methods, as discussed below. Nevertheless, several novel
genes (INSL3, SYCP1, WISP2, CST9L, FLJ35767,
DDR1) were identified for which the function or site of
expression suggested that they might be of particular
interest for further examination. The array analysis
indicated approximately 10-fold down-regulation of
INSL3 between controls and treated samples, with 2–
3-fold changes for FLJ35767, SYCP1 (only in the CTD
group), WISP2, and CST9L (only in the CT group) and
about 2-fold up-regulation of DDR1 in both groups.
Quantitative RT-PCR analysis (Figure 3A) on the
complete set of biopsy RNA samples (Walton et al,
2006) showed degrees of down-regulation similar to
those in the arrays for INSL3 (P , .001), SYCP1 (P ,
.01), WISP2 (P , .05), and FLJ35767 (P , .01) in both
treatment groups. FLJ35767 was the only gene identi-
fied for which expression was lower in the CTD group
than in the CT group (P 5 .03). INSL3 was lower in
suppressors than nonsuppressors in the CT group (18.7
6 3.5% compared with 36.5 6 0.6% relative to RPL32,
P , .012) but not in the CTD group. On the basis of
qRT-PCR, CST9L expression was actually increased to
a small but significant extent in both treatment groups
compared with controls, whereas DDR1 showed no
significant change.
The remaining genes identified as down-regulated
from this first stage of testing were CT45-1 and -3,
closely related cancer-testis antigens; PAPSS, 39-phos-
phoadenosine 59-phosphosulfate synthase 2, which is
involved in purine metabolism; and DPEP3 (MDB3), a
Table 1. Sequences of primers used for quantitative reverse transcriptase polymerase chain reaction
Gene Forward Primer Reverse Primer
Product Size,
bp
GenBank
Accession Reference
SYCP1 GCAAAAGCCCTTTGCATTGTTC ATGTTTTCCCCATTTTTGGAGAG 177 NM_003176 Primer 3
INSL3 CCCAGAGATGCGTGAGAAGT CCAGCGTGAGATTACTGTCG 185 NM_005543 "
WISP2 CTGTATCGGGAAGGGGAGA GGAAGAGACAAGGCCAGAAA 246 NM_003881 "
DDR1 CGTGTACCTCAACGACTCCA TGCTCCATCCCACATAGTCA 158 NM_013994 "
CST9L GACTGGGGCACATCTTGAAT GTGCTGATGGTGAAGAAGCA 178 NM_080610 "
FLJ35767 GAAGACAACTGGGACCCTGA CCTCCTGAGGCCATAGTTCA 220 NM_207459 "
PROK1 ACAAGGTCCCCTTCTTCAGGA GCAAGCGCCTAAAAATTGATGTT 133 NM_032414 BioTrove
PGRMC1 ATCAACGGCAAGGTGTTCGAT AAATGTGGCAAGGCCCCTG 108 NM_006667 BioTrove
RHOB CCCACCGTCTTCGAGAACTA CACCGAGAAGCACATGAGAA 153 NM_004040 Primer 3
APOE GGTCGCTTTTGGGATTACCT TTCCTCCAGTTCCGATTTGT 150 NM_000041 "
TAF4B CAGAAGACGATGCCAGTGAA GACCCCTGCCATAGAAGTCA 201 XM_290809 "
Table 2. Biological processes statistically overrepresented in
the testis
Gene Ontology Term
(Biological Processes) Count %a Enrichment P
Growth 20 0.37 .0055
Regulation of growth 44 0.81 .0048
Regulation of enzyme activity 71 1.31 .0414
Regulation of cellular process 842 15.57 .0314
Regulation of cell size 16 0.30 .0388
Death 159 2.94 .0430
Sexual reproduction 87 1.61 2.41 6 1028
Negative regulation of
biological process 221 4.09 .0018
Cellular physiological process 2708 50.07 7.02 6 10267
Cellular morphogenesis 16 0.30 .0388
Metabolism 2151 39.77 1.45 6 10241
Cell organization and
biogenesis 16 0.30 .0388
Cell growth 58 1.07 .000112
Locomotion 84 1.55 .000087
Localization 756 13.98 1.65 6 1026
Response to endogenous
stimulus 91 1.68 .0000879
a Number of gene hits out of 5824 genes in the filtered set.
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testis-specific dipeptidase involved in glutathione degra-
dation (Habib et al, 2003).
Analysis by Degree of Spermatogenic Suppression
Stage 2 testing (excluding men showing poor suppres-
sion of spermatogenesis) identified a further 5 genes
(SC4MOL, GSTA2, CHGA, PRPS2, CYB5; Table 3,
upper section) that were significantly down-regulated at
least 2-fold in the CT group relative to controls. Similar
down-regulation in the CTD group did not reach
significance, but there was no difference between CT
and CTD groups.
No statistically significant differences were identified
by the stage 3 test comparing sperm nonsuppressors and
suppressors in the 2 treatment groups. However, 4 genes
(PROK1, PGRMC1, APOE, RHOB; Table 3, lower
section) that had shown small (,2-fold) but statistically
significant reduction in expression between controls and
the CT group, but not the CTD group, after stage 1
testing also showed slightly higher expression in CTD
sperm suppressed samples compared with nonsup-
pressed samples. Although these array-based differences
were not significant, this potentially intriguing effect of
added progestogen was investigated further by qRT-
PCR analysis on the full set of 29 samples (Figure 3B).
This demonstrated that PROK1, PGRMC1, and RHOB
in fact showed significant 2–3-fold down-regulation
between control and all treated samples from both
groups, with no difference between nonsuppressors and
suppressors in either. APOE showed a 2–3-fold down-
regulation that was only significant in the CT group (P
5 .04), as in the arrays, but did not differ significantly
between nonsuppressors and suppressors within the
CTD group (P 5 .8).
Given the dominance of GnRH suppression over
progestogen-mediated effects and the absence of differ-
ences between the CT and CTD groups in terms of
global gene expression, a final round of testing
compared control samples with pooled CT and CTD
groups. This identified no additional genes.
TAF4B is a germ cell–specific transcription factor
that has recently been shown in the ovary to regulate
expression of a number of genes, including INHA and
RHOB (Geles et al, 2006). Because both INHA (Walton
et al, 2006) and RHOB (this study) were down-regulated
in the treatment groups, it seemed a likely possibility
that it occurs through regulation of TAF4B. Although
not identified in the array analysis (it neither passed the
nonspecific filter nor showed an at least 2-fold change
between groups), with the use of qRT-PCR (Figure 3C),
we demonstrated a small (30%) but significant reduction
in TAF4B expression in both treatment groups.
Clustering Analysis
Clustering analysis was also performed on the entire
RMA-normalized dataset with Biolayout Express3D
(Goldovsky et al, 2005; Freeman et al, in press). The
networks produced by the software consist of nodes that
represent individual transcripts connected by edges
representing similarities in their expression profiles
across multiple conditions. This approach allows the
rapid identification of biological relationships that could
be missed by conventional analysis techniques (ie,
statistical 2-sample tests). Several small cluster graphs
and 1 major graph of genes that contained 19 out of the
Figure 1. Volcano plots of the filtered gene set representing both
differential expression and its statistical significance. The x-axis
shows differential expression between 2 groups, and the y-axis
shows the statistical significance. Genes above the lower horizontal
dotted line have an adjusted P # .05. Genes above the upper
horizontal dotted line have an adjusted P # .01. Differences in
expression between CT (cetrorelix and testosterone) and CTD
(cetrorelix, testosterone, and desogestrel) groups were not signifi-
cant. Compared with control samples, only a small number of genes
showed differential expression and statistical significance.
Bayne et al N Gonadotropins and Testicular Function 393
20 probes from the original gene list were produced.
Following clustering with MCL, the statistical hits (620
probes) separated out into 2 distinct clusters. The first
cluster (cluster 1, Table 4) consisted of 66 probes,
including 4 of the original statistically significant probes
(CT45-1 [62], SYCP1, and DPEP3). The second cluster
(cluster 2, Table 5) consisted of 44 probes, including 9 of
the original statistically significant probes (INSL3 [63],
DHCR24, PAPSS2, CYP11A1, STAR, CYP17A1, and
HSD17B6). With the use of DAVID pathway analysis
software, cluster 1 showed enrichment for genes
involved in spermatogenesis, male gamete generation,
and gametogenesis, including early meiotic pathways
(Table 6), whereas cluster 2 showed enrichment for
genes involved in steroid, lipid, and cholesterol biosyn-
thesis/metabolism (Table 7).
Rank Product Analysis
Finally, as an independent means of assessing differ-
ential gene expression, the original data were subjected
to rank product analysis (Breitling et al, 2004). The
gene list generated by this method (data not shown)
was very similar to the expanded gene lists generated
from Biolayout Express3D, indicating that the addi-
tional genes identified are likely to have some
biological significance. A summary of the notable
genes identified in the screens, along with potential
functions and sites of expression within the testis, is
provided in Table 8.
Discussion
Microarray comparisons between biopsies of men
treated with GnRH antagonist plus or minus progesto-
gen and controls yielded a remarkably small subset of
genes that were altered between the 3 groups, with most
reflecting changes in Leydig cells. Cluster analysis
suggests that the genes fall into 2 distinct groups, with
one set of genes involved in gametogenesis and
spermatogenesis and the other involved in steroid and
cholesterol biosynthesis/metabolism. The significance of
the biological functions in the original gene lists are
increased in the expanded lists generated after cluster
analysis, suggesting a genuine biological relationship
between them. Further confirmation of the biological
significance of these expanded gene lists comes from the
very similar results obtained by the alternative rank
product method (Breitling et al, 2004).
The striking homogeneity both between individuals
and between treatment groups could paradoxically
reflect heterogeneity within the testis. Marked histolog-
ical variation in spermatogenic activity between nearby
tubules has been observed in men treated with regimens
similar to those here (McLachlan et al, 2002). Thus, the
biopsies will contain tubules with varying suppression
that are then averaged during processing, potentially
leading to smaller apparent changes in gene expression
within the tubule compartments. Sertoli cell and
spermatogonial genes are also likely to be highly
Figure 2. Graphical representation of log2-fold changes in expression in the CT (cetrorelix and testosterone; black bars) and CTD (cetrorelix,
testosterone, and desogestrel; gray bars) groups relative to controls for each gene identified in the stage 1 test of array data. Bars below the line
represent n-fold decreases, whereas those above the line represent increases in expression. * P , .05, ** P , .01, *** P , .001 compared
with controls.
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Figure 3. Quantitative reverse transcriptase polymerase chain reaction analysis of expression of (A) significant genes of interest identified after
stage 1 testing, (B) genes identified as showing notable expression changes between suppressor (CT supp. and CTD supp.) and
nonsuppressor (ns., light grey bars) subgroups after stage 3 testing, and (C) TAF4B, an associated transcription factor of RHOB, in controls
(dark grey bars) and men in CT (cetrorelix and testosterone; black bars) and CTD groups (cetrorelix, testosterone, and desogestrel; white bars)
(x¯ 6 SEM). Gene expression is relative to RPL32. * P , .05, ** P, .01, *** P , .001 compared with controls; 4 P , .05 CTD vs CT group (n5
7–10 per group except nonsuppressors, in which n 5 5).
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underrepresented in RNA from total testis biopsies
because the major cellular component will be postmei-
otic germ cells, thus reducing the sensitivity to changes
in these cells. This is a limitation of the use of whole-
testis biopsies. Meanwhile, more consistent changes will
be observed in genes confined to Leydig cells and thus
will be more pronounced. In addition, some genes might
be expressed in many cell types but only regulated by
gonadotropins in, for example, Leydig cells. This will
lead to a robust expression level that partially masks
changes in one cell type between control and treated
samples.
Previously (Walton et al, 2006), we identified a small
number of genes by qRT-PCR in which expression was
reduced in at least 1 of the treatment groups, but only 1
of these (CYP17A1) overlapped with the genes identified
here by array analysis. Probes for all of the other genes
were present on the arrays, but in a number of cases
(SRD5A1, HSD3B2, MAGEA4), their expression level
was below the filtering threshold; therefore, they were
excluded from the analysis. The remaining genes
(INHA, PEPP-2, ACRBP) were present in the filtered
gene set but did not show a greater than 2-fold change in
hybridization and did not show statistical significance
better then P # .05. Although a very useful tool, it is
well known that arrays are less sensitive than qRT-PCR
in detecting small changes in gene expression, especially
with modest numbers of clinical samples, and many of
the changes we observed by qRT-PCR were only around
2-fold and therefore close to the cut-off level. In
addition, these genes are expressed in the tubule
compartment so intertubule variation in suppression as
mentioned above could have had an effect here.
Overall, the most significant changes identified were in
expression of genes involved in cholesterol biosynthesis/
metabolism and steroidogenesis, which are directly
sensitive to the concentration of LH acting on Leydig
cells. Also within this group, SC4MOL, which is involved
in cholesterol biosynthesis (Li and Kaplan, 1996), and
CYB5, the product of which binds and allosterically
modulates CYP17 in Leydig cells (Dharia et al, 2004),
showed small changes in expression. APOE has many
functions, but its role in cholesterol homeostasis (Levi et
al, 2005) could also be relevant in this context. The
observation that APOE was significantly down-regulated
in the CT but not the CTD group suggests that
progestogens, known to regulate Leydig cell steroidogen-
esis (El-Hefnawy et al, 2000), might affect its expression.
The only other gene observed to show a dramatic
reduction in expression was INSL3, which is also
expressed in Leydig cells. Serum concentrations were
not affected by hCG administration to normal men
(Bay et al, 2005); however, LH suppression resulted in
reduced INSL3 concentrations (Bay et al, 2006).
INSL3 is known to be induced by the transcription
factor NR4A1 (Nur77) (Robert et al, 2006), which is
expressed at low levels but is rapidly and robustly
induced by LH and cyclic adenosine monophosphate
analogs and is thought to mediate the dynamic
expression of INSL3 in response to LH (Robert et al,
2006). The steroidogenic enzyme genes 3BHSD2,
CYP17A1, and STAR are also activated by NR4A1
(Zhang and Mellon, 1997; Martin and Tremblay,
2005). Thus, reduced LH will lead to reduced NR4A1
(expression of which was below the threshold to detect
changes in the array), which will produce lower levels
Table 3. Log2-fold changes in expression and P values of stage 2 and 3 genes of interest
a
Probe Symbol
Stage 1 Testing Stage 2 Testing
Control vs CT Control vs CTD Control vs CTb Control vs CTDb
Log2-Fold
Change P
Log2-Fold
Change P
Log2-Fold
Change P
Log2-Fold
Change P
209146_at SC4MOL 0.96 .011 1.01 .092 1.04 .028 0.98 0.141
203924_at GSTA2 0.93 .05 0.73 .205 1.15 .048 0.7 0.254
204697_s_at CHGA 0.93 .028 0.9 .061 1.11 .028 0.89 0.096
203401_at PRPS2 0.9 .007 0.66 .221 1.06 .008 0.61 0.272
215726_s_at CYB5 0.89 .01 0.82 .028 1.01 .021 0.81 0.061
Stage 3 Testing
CTDsupp vs ns Log2-Fold Change
229124_at PROK1 0.88 .044 0.5 .445 0.75
201120_s_at PGRMC1 0.83 .013 0.69 .291 0.51
203382_s_at APOE 0.8 .044 0.4 .554 0.81
212099_at RHOB 0.59 .009 0.43 .47 0.51
Abbreviations: CT, cetrorelix and testosterone; CTD, cetrorelix, testosterone, and desogestrel; ns, nonsuppressors; supp, suppressors.
a Data in bold are referred to in the text.
b Without nonsuppressors.
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of 3BHSD2, CYP17A1, STAR, and INSL3, all of
which we have observed here or reported previously
(Walton et al, 2006). Recently, it has been demonstrat-
ed that serum INSL3 concentrations are higher in
nonsuppressors than suppressors on male contracep-
tive regimens (Amory et al, 2007). In this context, it is
notable that we also observed higher levels of INSL3
transcripts in nonsuppressors compared with suppres-
sors in the CT group (but not the CTD group).
The receptor for INSL3, LGR8, is expressed in both
Leydig cells and in meiotic and postmeiotic germ cells
but not in Sertoli or peritubular cells (Kawamura et al,
2004; Anand-Ivell et al, 2006). Insl3 knockout mice
show cryptorchidism and INSL3 regulates apoptosis in
germ cells in both male and female mice (Kawamura et
al, 2004). Because germ cells do not express gonadotro-
pin receptors, germ cell genes cannot be directly
regulated by gonadotropins. INSL3 might therefore
provide a link between Leydig cells and spermatogen-
esis, which could contribute to the changes in gene
expression levels observed here in the germ cell
compartment, such as for SYCP1, a gene essential for
chromosomal synapsis at prophase I of meiosis and
detected in the stage 1 screen, as well as SYCP3, DMC1,
DAZ1,MSH5, TEX11, TEX14, TEX101, and HOR-
MAD1 and 2, which were identified from the cluster
analysis. We detected previously (Walton et al, 2006) a
reduced expression of ACRBP, a spermatocyte-specific
marker in the CTD and suppressor groups, and of
MAGEA4, which is present in spermatogonia and
primary spermatocytes, in the suppressor group. In
contrast, expression of PRM1, a postmeiotic germ cell
marker, remained unchanged. Together with these new
early meiotic genes, this further implicates an effect of
the treatments on early stages of spermatogenesis. What
is currently less clear is whether the reduced expression
of germ cell markers after treatment is due to small
changes in gene expression within germ cells or loss of a
percentage of early germ cells, as has been observed at
the histological level under similar regimens (McLachlan
et al, 2002). Both would yield the same result. This could
be resolved by histochemical analysis of biopsies for
these gene products, but insufficient material was
available to us for this.
Table 4. Cluster analysis: expanded list of genes showing
expression profiles similar to genes identified as statistically
significant—cluster 1a
Probe Gene Symbol Probe Gene Symbol
1553285_s_at RAD9B 213404_s_at RHEB
1553599_a_at SYCP3 216917_s_at SYCP1
1554768_a_at MAD2L1 218370_s_at S100PBP
1556554_at TRIM50 218683_at PTBP2
1560912_at LOC389043 218768_at NUP107
1564688_a_at RAD9B 220126_at TSP50
1567912_s_at CT45-1 220179_at DPEP3
200996_at ACTR3 221035_s_at TEX14
201291_s_at TOP2A 221259_s_at TEX11
201292_at TOP2A 221521_s_at GINS2
201614_s_at RUVBL1 222848_at CENPK
201697_s_at DNMT1 223542_at ANKRD32
201738_at EIF1B 223861_at HORMAD1
201965_s_at SETX 223906_s_at TEX101
202033_s_at RB1CC1 225783_at UBE2F
203062_s_at MDC1 226779_at No class
203362_s_at MAD2L1 227085_at H2AFV
203755_at BUB1B 227818_at CCDC21
203947_at CSTF3 227894_at WDR90
204033_at TRIP13 228171_s_at PLEKHG4
204900_x_at SAP30 230236_at LOC732253
205292_s_at HNRPA2B1 231210_at LOC283129
205995_x_at IQCB1 233514_x_at TEX11
206052_s_at SLBP 234296_s_at TEX11
207909_x_at DAZ1/DAZ3/
DAZ2/DAZ4
235557_at LOC150763
208282_x_at DAZ1/DAZ3/
DAZ2/DAZ4
235700_at CT45-1
208382_s_at DMC1 236811_at DMRTC2
208821_at SNRPB 236852_at FBXO43
209674_at CRY1 237170_at . . .
210410_s_at MSH5 237781_at HORMAD2
211707_s_at IQCB1 238508_at DBF4B
211953_s_at RANBP5 239824_s_at TMEM107
212666_at SMURF1 240546_at LOC389043
a Probes in bold represent those identified in the initial analysis as
statistically significant, with novel probe hits in normal font.
Table 5. Cluster analysis: expanded list of genes showing
expression profiles similar to genes identified as statistically
significant—cluster 2a
Probe Gene Symbol Probe Gene Symbol
1553594_a_at INSL3 209146_at SC4MOL
200862_at DHCR24 209366_x_at CYB5A
200969_at SERP1 210130_s_at TM7SF2
201120_s_at PGRMC1 210367_s_at PTGES
201121_s_at PGRMC1 212297_at ATP13A3
201790_s_at DHCR7 214400_at INSL3
201791_s_at DHCR7 214572_s_at INSL3
202068_s_at LDLR 215506_s_at DIRAS3
202539_s_at HMGCR 215726_s_at CYB5A
202540_s_at HMGCR 217014_s_at AZGP1
203058_s_at PAPSS2 222102_at GSTA3
203060_s_at PAPSS2 223734_at OSAP
203924_at GSTA1 225305_at SLC25A29
204309_at CYP11A1 225373_at C10orf54
204526_s_at TBC1D8 226613_at LOC652968
204548_at STAR 227506_at SLC16A9
205428_s_at CALB2 228754_at SLC6A6
205502_at CYP17A1 228885_at MAMDC2
205700_at HSD17B6 229789_at TIGD3
207695_s_at IGSF1 230352_at PRPS2
207843_x_at CYB5A 231948_s_at UBE2F
207935_s_at KRT13 37512_at HSD17B6
a Probes in bold represent those identified in the initial analysis as
statistically significant, with novel probe hits in normal type.
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Table 6. Enrichment of gene ontologies in expanded gene lists: DAVID pathway analysis of cluster 1a
Gene Ontology Term No. of Genes %b Enrichment P Gene Symbol
DNA metabolism
11 18.64 2.30 6 1026
MSH5, DNMT1, TOP2A, GINS2, DMC1, RUVBL1, SYCP1,
CRY1, H2AFV, MDC1, RAD9B
Biopolymer metabolism
20 33.90 4.81 6 1026
HNRPA2B1, SLBP, GINS2, DMC1, RUVBL1, H2AFV, BUB1B,
UBE2F, MSH5, SNRPB, DNMT1t, TOP2A, CRY1, SYCP1,
TEX14, SMURF1, MDC1, CSTF3, RAD9B, PTBP2
Nucleobase, nucleoside,
nucleotide, and nucleic
acid metabolism 20 33.90 1.19 6 1024
HNRPA2B1, SLBP, GINS2, TRIP13,DMC1, RUVBL1, H2AFV,
RB1CC1, MSH5, SNRPB, DNMT1, TOP2A, CRY1, SYCP1,
SAP30, MDC1, CSTF3, RAD9B, DMRTC2, PTBP2
Macromolecule metabolism
23 38.98 1.68 6 1024
HNRPA2B1, SLBP, GINS2, DMC1, RUVBL1t TSP50, H2AFV,
EIF1B, BUB1B, UBE2F,MSH5, SNRPB, DNMT1, TOP2A,
TEX14, CRY1, SYCP1, SMURF1, MDC1, CSTF3, RAD9B,
PTBP2, DPEP3
Male gamete generation 5 8.47 3.336 1024 DAZ1 DAZ3 DAZ2 DAZ4, DMC1, RUVBL1, SYCP1
Spermatogenesis 5 8.47 3.336 1024 DAZ1 DAZ3 DAZ2 DAZ4, DMC1, RUVBL1, SYCP1
Gametogenesis 5 8.47 6.986 1024 DAZ1 DAZ3 DAZ2 DAZ4, DMC1, RUVBL1, SYCP1
DNA recombination 4 6.78 7.34 6 1024 MSH5, DMC1, RUVBL1, SYCP1
Meiotic recombination 3 5.08 8.876 1024 MSH5, DMC1, SYCP1
M phase 5 8.47 .001109199 MSH5, DMC1, SYCP1, MAD2L1, MDC1, BUB1B
Cell cycle
8 13.56 .001228391
MSH5, DMC1, SYCP1, RB1CC1, MAD2L1, MDC1, RAD9B,
BUB1B
Meiosis I 3 5.08 .001420763 MSH5, DMC1, SYCP
Sexual reproduction 5 8.47 .001557728 DAZ1 DAZ3 DAZ2 DAZ4, DMC1,RUVBL1, SYCP1
DNA repair 5 8.47 .002119799 MSH5, TOP2A, CRY1, MAD2L1, RAD9B
Response to DNA damage
stimulus 5 8.47 .003055314
MSH5, TOP2A, CRY1, MAD2L1, RAD9B
Response to endogenous
stimulus 5 8.47 .003832754
MSH5, TOP2A, CRY1, MAD2L1, RAD9B
Reproduction 5 8.47 .003832754 DAZ1 DAZ3 DAZ2 DAZ4, DMC1, RUVBL1, SYCP1
Primary metabolism
27 45.76 .005542536
GINS2, DMC1, H2AFV, RB1CC1, BUB1B, UBE2F, MSH5,
TOP2A, DNMT1, CRY1, TEX14, SAP30, MDC1, PTBP2,
HNRPA2B1, TRIP13, SLBP, RUVBL1, TSP50, EIF1B,
DNMT1, SNRPB, SMURF1, CSTF3, RAD9B, DMRTC2,
DPEP3
Meiosis 3 5.08 .005605975 MSH5, DMC1, SYCP1
M phase of meiotic cell
cycle 3 5.08 .005605975
MSH5, DMC1, SYCP1
Meiotic cell cycle 3 5.08 .005835985 MSH5, DMC1, SYCP1
Cellular metabolism
27 45.76 .009990932
GINS2, DMC1, H2AFV, RB1CC1, BUB1B, UBE2F, MSH5,
TOP2A, SYCP1, CRY1, TEX14, SAP30, MDC1, PTBP2,
HNRPA2B1, TRIP13, SLBP, RUVBL1, TSP50, EIF1B,
DNMT1, SNRPB, SMURF1, CSTF3, RAD9B, DMRTC2,
DPEP3
RNA processing 5 8.47 .010524072 HNRPA2B1, SNRPB, SLBP, CSTF3, PTBP2
Metabolism
28 47.46 .012775914
GINS2, DMC1, H2AFV, RB1CC1, BUB1B, UBE2F, MSH5,
TOP2A, SYCP1, CRY1t, TEX14, SAP30, MDC1, PTBP2,
HNRPA2B1, TRIP13, SLBP, RUVBL1, TSP50, EIF1B,
DNMT1, SNRPB, LOC150763, SMURF1, CSTF3, RAD9B,
DMRTC2, DPEP3
mRNA processing 4 6.78 .012824716 SNRPB, SLBP, CSTF3, PTBP2
mRNA metabolism 4 6.78 .01788918 SNRPB, SLBP, CSTF3, PTBP2
RNA metabolism 5 8.47 .022531644 HNRPA2B1, SNRPB, SLBP, CSTF3, PTBP2
RNA 39-end processing 2 3.39 .025443074 SLBP, CSTF3
mRNA 39-end processing 2 3.39 .025443074 SLBP, CSTF3
Cellular physiological
process
32 54.24 .029135935
NUP107, GINS2, DMC1, H2AFV, RB1CC1, RANBP5, MAD2L1,
BUB1B,UBE2F, MSH5, TOP2A, TOP2A, SYCP1, CRY1,
TEX14, SAP30, MDC1, PTBP2, SETX, HNRPA2B1, SLBP,
TRIP13, RUVBL1, TSP50, EIF1B, SNRPB, DNMT1,
SMURF1, CSTF3, RAD9B, DMRTC2, ACTR3, DPEP3
Mitotic checkpoint 2 3.39 .032272232 MAD2L1, MAD2L1, BUB1B
a Major relevant pathways and genes are marked in bold.
b Out of a total number of 59 separate genes in the cluster.
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Further genes known to be expressed by Leydig cells
and showing significant down-regulation during gonad-
otropin suppression were CHGA and PROK1. Expres-
sion of CHGA correlates with LH levels (Ortega et al,
2004). However, in the bovine testis, CHGA expression
is also high in spermatogonia (Payan-Carreira et al,
2006) with a reducing gradient of expression with
maturation up to the round spermatid stage. Elongating
and elongated spermatids do not express CHGA. Thus,
reduced expression of CHGA in the treated men might
also reflect suppression of spermatogenesis. PROK1, a
prokineticin, encodes EG-VEGF, which is expressed in
Leydig cells and is thought to be involved in the integrity
and proliferation of blood vessels in the testis (Samson
et al, 2004). Knock-out in mice of 1 of its receptors,
Pkr2, causes severe atrophy of the reproductive system
(Matsumoto et al, 2006), an effect partly due to low
concentrations of gonadotropins associated with lack of
GnRH but also thought to have a direct testicular
component. In the ovary, expression of PROK1
positively correlates with granulosa cell steroidogenesis
(Kisliouk et al, 2003).
PGRMC1 (HPR6) encodes a component of the
putative membrane progesterone receptor and is able
to activate cytochrome P450 enzymes (Crudden et al,
2005). A reduction in its expression might therefore
contribute to reduced expression of such enzymes. The
array data suggested suppression in the CT but not
CTD groups, but qRT-PCR analysis demonstrated
similar suppression in both groups.
Although small changes in expression could simply be
due to loss of a proportion of some germ cell types,
alteration in the dynamics of Sertoli cell–germ cell
adherens junctions was suggested by changes in
expression of RHOB, a member of the RAS gene family
(Lui et al, 2003). The breakdown of adherens junctions
is necessary for germ cells to detach from Sertoli cells at
spermiation, suggesting the possibility that reduction in
expression of RHOB and its associated regulatory
transcription factor TAF4B (Geles et al, 2006) could
Table 7. Enrichment of gene ontologies in expanded gene lists: DAVID pathway analysis of cluster 2a
Gene Ontology Term No. of Genes %a Enrichment P Gene Symbol
Steroid biosynthesis
9 25.71 1.33 6 10212
HSD17B6, HMGCR, DHCR24, SC4MOL, CYP11A1, STAR,
TM7SF2, CYP17A1, DHCR7
Steroid metabolism
10 28.57 1.22 6 10211
HSD17B6, HMGCR, DHCR24,SC4MOL, CYP11A1, LDLR,
STAR, TM7SF2, CYP17A1, DHCR7
Sterol metabolism
7 20.00 5.17 6 1029
HMGCR, DHCR24, SC4MOL, CYP11A1, LDLR, TM7SF2,
DHCR7
Lipid biosynthesis
9 25.71 7.56 6 1029
HSD17B6, HMGCR, DHCR24, SC4MOL, CYP11A1, STAR,
TM7SF2, CYP17A1, DHCR7
Lipid metabolism
12 34.29 1.19 6 1028
HSD17B6, HMGCR, DHCR24, SC4MOL, CYP11A1, LDLR,
PTGES, STAR, TM7SF2, CYP17A1, AZGP1, DHCR7
Cellular lipid metabolism
11 31.43 1.70 6 1028
HSD17B6, HMGCR, DHCR24, SC4MOL, CYP11A1, LDLR,
PTGES, STAR, TM7SF2, CYP17A1, DHCR7
Cholesterol metabolism 6 17.14 1.34 6 1027 HMGCR, DHCR24, CYP11A1, LDLR, TM7SF2, DHCR7
Sterol biosynthesis 5 14.29 1.94 6 1027 HMGCR, DHCR24, SC4MOL, TM7SF2, DHCR7
Cholesterol biosynthesis 4 11.43 9.84 6 1026 HMGCR, DHCR24, TM7SF2, DHCR7
Alcohol metabolism
7 20.00 1.78 6 1025
HMGCR, DHCR24, SC4MOL, CYP11A1, LDLR, TM7SF2,
DHCR7
Hormone biosynthesis 4 11.43 2.08 6 1025 HSD17B6, CYP11A1, STAR, CYP17A1
Biosynthesis
12 34.29 6.25E-05
HSD17B6, HMGCR, DHCR24, SC4MOL, CYP11A1, PRPS2,
LDLR, SERP1, STAR, TM7SF2, CYP17A1, DHCR7
Hormone metabolism 4 11.43 1.14 6 1024 HSD17B6, CYP11A1, STAR, CYP17A1
C21-steroid hormone
biosynthesis 3 8.57 1.97 6 1024
CYP11A1, STAR, CYP17A1
C21-steroid hormone
metabolism 3 8.57 2.37 6 1024
CYP11A1, STAR, CYP17A1
Androgen biosynthesis 2 5.71 .005804242 HSD17B6, CYP11A1
Androgen metabolism 2 5.71 .01157595 HSD17B6, 2CYP11A1
Cellular biosynthesis
8 22.86 .012738723
HSD17B6, HMGCR, CYP11A1, PRPS2, LDLR, PGRMC1,
STAR, CYP17A1
Metabolism
23 65.71 .032542447
CYB5A, GSTA3, GSTA1, HMGCR, SC4MOL, LDLR, PRPS2,
ATP13A3, CYP17A1, AZGP1, UBE2F, TIGD3, HSD17B6,
PAPSS2, DHCR24, CYP11A1, SLC6A6, PTGES,
STAR,PGRMC1, TM7SF2, DIRAS3, DHCR7
a Out of a total number of 35 separate genes in the cluster.
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Table 8. Summary of genes identified
Gene Symbol Full Gene Name Gene Ontology Function Cellular Localizationa
CYP17A1 Cytochrome P450c17-alpha-hydroxylase/
17,20-lyase
C21-steroid hormone biosynthesis Leydig cells
CYP11A1 Cytochrome P450c11 side-chain cleavage C21-steroid hormone biosynthesis Leydig cells
HSD17B6 Hydroxysteroid (17-beta) dehydrogenase 6
homolog
Androgen biosynthesis Leydig cells
STAR Steroidogenic acute regulatory protein Steroid biosynthesis Leydig and Sertoli
cells
DHCR24 24-Dehydrocholesterol reductase Cholesterol biosynthesis, MAP kinase phosphatise
activity
Spermatogonia,
Sertoli and Leydig
cells
DPEP3 Dipeptidase 3 Membrane dipeptidase activity Spermatocytes,
Leydig cells
GSTA2 Glutathione S-transferase A2 Glutathione transferase activity Spermatogonia
PRPS2 Phosphoribosyl pyrophosphate synthetase 2 Kinase activity; nucleoside, nucleotide, and nucleic
acid biosynthesis; and metabolism
Sertoli cells,
spermatogonia,
Leydig cells
PAPSS 39-Phosphoadenosine 59-phosphosulfate
synthase
Adenylylsulfate kinase activity; ATP binding;
nucleobase, nucleoside, nucleotide, and nucleic
acid metabolism; nucleotidyltransferase activity
Germ cells, Leydig
cells
HMGCS2 3-Hydroxy-3-methylglutaryl-coenzyme A
synthase 2 (mitochondrial)
Cholesterol biosynthesis Spermatogonia
CT45-1, 3 Cancer/testis antigen CT45-1/3 Unknown Testis
INSL3 Insulinlike 3 (Leydig cell) Cell-cell signaling, hormone activity, insulin receptor
binding, spermatogenesis
Leydig cells
SC4MOL Sterol-C4-methyl oxidaselike Steroid metabolism, sterol biosynthesis, C-4
methylsterol oxidase activity
Sertoli cells,
spermatogonia
CYB5 Cytochrome b5 Cytochrome c oxidase activity, fatty acid metabolism,
transport
Spermatogonia,
Leydig cells
APOE Apolipoprotein E Cholesterol homeostasis, induction of apoptosis, lipid
transport, lipoprotein metabolism, antioxidant
activity
Sertoli cells,
spermatogonia
TAF4B TAF4b RNA polymerase II, TATA box binding
protein (TBP)–associated factor, 105 kd
Transcription factor activity Spermatogonia,
Sertoli and Leydig
cells
SYCP1 Synaptonemal complex protein 1 Synaptonemal complex formation, DNA binding,
meiotic recombination, spermatogenesis
Spermatogonia,
spermatocytes
SYCP3 Synaptonemal complex protein 3 Synaptonemal complex formation, DNA binding,
meiotic recombination, spermatogenesis
Spermatocytes
DMC1 DMC1 dosage suppressor of mck1 homolog ATP binding, damaged DNA binding, DNA repair,
meiotic recombination, spermatogenesis
Germ cells, Leydig
cells
DAZL Deleted in azoospermialike Cell differentiation, nucleotide binding, regulation of
translation, RNA binding, spermatogenesis
Spermatogonia,
spermatocytes
MSH5 mutS Homolog 5
TEX11 Testis expressed 11 Protein binding Spermatogonia,
Leydig cells
TEX14 Testis expressed 14 Nucleotide binding, protein amino acid
phosphorylation, protein kinase activity, transferase
activity
Germ cells, Leydig
cells
TEX101 Testis expressed 101 Receptor activity Spermatocytes,
Leydig cells
HORMAD1 HORMA domain containing 1 DNA-binding HORMA Spermatocytes,
Leydig cells
HORMAD2 HORMA domain containing 2 DNA-binding HORMA Germ cells, Leydig
cells
CHGA Chromogranin A Calcium ion binding Germ cells
PROK1 Prokineticin 1, (EG-VEGF) Growth factor activity Germ cells
PGRMC1 Progesterone receptor membrane
component 1
Receptor activity, steroid binding Spermatogonia,
Leydig cells
RHOB ras Homolog gene family, member B Cell adhesion, cell differentiation, nucleotide binding,
protein binding, protein transport, transformed cell
apoptosis
Spermatogonia,
Sertoli and Leydig
cells
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block this process as a mechanism for the failure of
spermiation observed during male contraceptive regi-
mens (Matthiesson and McLachlan, 2006). RhoB
expression at adherens junctions is increased by 1-(2,
4-dichlorobenzyl)-indazole-3-carbohydrazide (adjudin),
which interferes with adhesion of spermatids and
spermatocytes to Sertoli cells, and hence their matura-
tion, and is a promising approach to reversible male
contraception (Lui et al, 2003; Mruk et al, 2006). The
WNT1 pathway is also involved in the regulation of
adherens junctions (Wechezak and Coan, 2003), and
WISP2, a component of the WNT1 signaling pathway
(Banerjee et al, 2003), was reduced in both treatment
groups. A further potential gene associated with
regulation of adherens junctions and the only gene
identified as increased in both treatment groups is
CST9L, a cysteine protease inhibitor (Siu and Cheng,
2004).
Of the remaining genes in which levels were observed
to fall in the treated groups, PAPSS and PRPS2 are
genes involved in nucleotide metabolism, and GSTA2
and DPEP3 have a function in glutathione metabolism.
Both of these biological processes were found to be
statistically overrepresented in the testis when higher
level gene ontology and KEGG (Kyoto Encyclopedia of
Genes and Genomes) analysis was performed on the
expressed gene set (P 5 .03 and .05, respectively),
indicating their importance in the testis.
Very few genes were differentially suppressed between
the 2 treatment groups. Some were only significantly
different from controls in one group (eg, CT group:
APOE, HSD17B6, STAR, PRPS2, GSTA2; CTD
group: SYCP1, DPEP3), but qPCR analysis showed
significantly different expression in CT compared with
CTD in only 1 gene, FLJ35767. This is an expressed
sequence tag (EST) isolated from a human testis library
in which the predicted coding sequence shows similarity
to 2 mouse proteins, Tex19 and a hypothetical protein.
Tex19 is expressed in spermatogonia (Wang et al, 2001).
The finding that FLJ35767 is down-regulated further by
desogestrel than by a GnRH antagonist and testoster-
one alone suggests a progestogenic effect, as we have
previously reported for SRD5A1 (Walton et al, 2006).
This provides further evidence for direct progestogenic
effects on the testis. However, it is striking that only 1
such gene was identified in this study, indicating that it
might be of limited biological significance. The absence
of any significant differences between suppressors and
nonsuppressors (other than for INSL3) within the
treatment groups was disappointing. Given that the
data were so tight between individuals, it seems likely
that an array approach will require more refined tissue
sampling to be of value in this key issue.
In this study, we identify the 10% of genes most highly
expressed in the human testis. Only a small subset of
genes was observed to show changes in expression after
4 weeks of gonadotropin suppression. Functional
grouping indicates that genes associated with steroido-
genesis are most markedly regulated by short-term
gonadotropin suppression, with other Leydig cell genes
also highly regulated, most notably INSL3. INSL3
might be a candidate for future contraceptive targeting.
Within the tubule compartment, genes involved in early
meiosis showed reduced expression, with regulation of a
number of genes that might be involved with adherens
junctions also identified. Such changes could underlie
the observation that disruption of spermiation is an
early component of the response to gonadotropin
withdrawal. Future studies examining histological ex-
pression of these genes should help define whether they
are down-regulated in individual cells or whether certain
early germ cell stages expressing them are lost because of
a lack of gonadotropin support.
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